Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene is homologous to the murine protein MCAP, which associates with chromosomes during mitosis, and to the human RING3 protein, a serine/threonine kinase. Each of these proteins contains two bromodomains, a conserved sequence motif which may be involved in chromatin targeting. This gene has been implicated as the chromosome 19 target of translocation t(15;19)(q13;p13.1), which defines an upper respiratory tract carcinoma in young people. Two alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]
BRD4 (Bromodomain Containing 4) is a Protein Coding gene. Diseases associated with BRD4 include Nut Midline Carcinoma and Exophthalmic Ophthalmoplegia. Among its related pathways are Chromatin Regulation / Acetylation. Gene Ontology (GO) annotations related to this gene include chromatin binding and lysine-acetylated histone binding. An important paralog of this gene is BRD2.
Bromodomains (BRDs) are epigenetic reader domains that selectively recognize acetylated lysine residues on the tails of histone proteins, and are the only known protein modules that can target acetylated lysine residues.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0002039 | p53 binding | IDA | 23317504 |
GO:0003682 | chromatin binding | IDA | 20871596 |
GO:0003712 | transcription coregulator activity | IMP | 24360279 |
GO:0005515 | protein binding | IEA,IPI | 17023018 |
GO:0008353 | RNA polymerase II CTD heptapeptide repeat kinase activity | IMP | 22509028 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000794 | condensed nuclear chromosome | IDA | 10938129 |
GO:0005634 | nucleus | IEA,IDA | 20871596 |
GO:0005654 | nucleoplasm | IDA | -- |
GO:0005694 | chromosome | IEA | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Chromatin Regulation / Acetylation |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000083 | regulation of transcription involved in G1/S transition of mitotic cell cycle | IMP | 18039861 |
GO:0006325 | chromatin organization | IEA | -- |
GO:0006468 | protein phosphorylation | IEA | -- |
GO:0006974 | cellular response to DNA damage stimulus | IEA | -- |
GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | IMP | 10938129 |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Olaparib | Approved | Pharma | PARP inhibitor, PARP Inhibitors, Other, Poly(ADPRIBOSE) polymerase (PARP) inhibitors | 277 | ||
rituximab | Approved | Pharma | Therapeutic Antibodies | 2024 | ||
Fedratinib | Approved, Investigational | Pharma | 0 | |||
CPI-203 | Pharma | BET bromodomain inhibitor | 0 | |||
I-BET-762 | Pharma | BET inhibitor,highly potent | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
I-BET 151 dihydrochloride |
|
1883545-47-8 |
|
|
||
PFI 1 |
|
1403764-72-6 |
|
|
Compound | Action | Cas Number |
---|---|---|
(+)-JQ1 | Potent, selective BET bromodomain inhibitor; cell permeable | 1268524-70-4 |
Bromosporine | Broad spectrum bromodomain inhibitor | |
I-BET 151 dihydrochloride | BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes | 1883545-47-8 |
Ischemin sodium salt | CBP inhibitor; cell permeable | |
PFI 1 | BET bromodomain inhibitor | 1403764-72-6 |
Compound | Action | Cas Number |
---|---|---|
(-)-JQ1 | BET bromodomain inhibitor | 1268524-71-5 |
BAZ2-ICR | ||
BET bromodomain inhibitor | Potent and selective inhibitor for BRD4 | 1380087-89-7 |
Bromodomain Inhibitor, (+)-JQ1 | BET bromodomain inhibitor | 1268524-70-4 |
Bromosporine | Bromodomain inhibitor,non-selective | 1619994-69-2 |
CPI-203 | BET bromodomain inhibitor | 1446144-04-2 |
GSK 525768A | inactive stereoisomer of I-BET-762 | 1260530-25-3 |
GSK 5959 | 901245-65-6 | |
GSK1324726A | BET proteins inhibitor | 1300031-52-0 |
I-BET 151 hydrochloride | ||
I-BET151 (GSK1210151A) | Selective BET inhibitor | 1300031-49-5 |
I-BET-762 | BET inhibitor,highly potent | 1260907-17-2 |
Ischemin sodium salt | ||
MS436 | BRD4 inhibitor | 1395084-25-9 |
OF-1 | BRPF1B and BRPF2 bromodomain inhibitor | 919973-83-4 |
OTX-015 | BRD inhibitor | 202590-98-5 |
OXF BD 02 | 1429129-68-9 | |
PFI-1 (PF-6405761) | BET inhibitor | 1403764-72-6 |
RVX-208 | Potent BET bromodomain inhibitor | 1044870-39-4 |
UNC1215 | Chemical probe for the methyllysine (Kme) | 1415800-43-9 |
UNC669 | L3MBTL antagonist,potent and selective | 1314241-44-5 |
ExUns: | 1 | ^ | 2 | ^ | 3 | ^ | 4 | ^ | 5 | ^ | 6 | ^ | 7 | ^ | 8 | ^ | 9 | ^ | 10 | ^ | 11 | ^ | 12 | ^ | 13 | ^ | 14 | ^ | 15 | ^ | 16a | · | 16b | ^ | 17a | · | 17b | ^ | 18 | ^ | 19 | ^ | 20 | ^ | 21 | ^ | 22 | ^ | 23 | ^ | 24a | · |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP2: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP3: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP4: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP5: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP6: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP7: | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
SP8: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP9: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP10: | - | |||||||||||||||||||||||||||||||||||||||||||||||||||
SP11: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP12: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
SP13: |
ExUns: | 24b | ^ | 25 | ^ | 26 | ^ | 27 | ^ | 28 | ^ | 29 | ^ | 30 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | |||||||||||||
SP2: | |||||||||||||
SP3: | |||||||||||||
SP4: | |||||||||||||
SP5: | |||||||||||||
SP6: | |||||||||||||
SP7: | |||||||||||||
SP8: | |||||||||||||
SP9: | |||||||||||||
SP10: | |||||||||||||
SP11: | |||||||||||||
SP12: | |||||||||||||
SP13: |
This gene was present in the common ancestor of animals.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Dog (Canis familiaris) |
Mammalia | BRD4 31 |
|
OneToOne | |
Chimpanzee (Pan troglodytes) |
Mammalia | BRD4 30 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | BRD4 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Brd4 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | BRD4 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | BRD4 31 |
|
OneToOne | |
Chicken (Gallus gallus) |
Aves | BRD4 31 |
|
OneToOne | |
LOC100859056 30 |
|
||||
Lizard (Anolis carolinensis) |
Reptilia | BRD4 31 |
|
OneToOne | |
Zebrafish (Danio rerio) |
Actinopterygii | brd4 31 |
|
OneToOne | |
Fruit Fly (Drosophila melanogaster) |
Insecta | fs(1)h 31 32 |
|
OneToMany |
SNP ID | Clinical significance and condition | Chr 19 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
710756 | Benign: not provided | 15,238,836(-) | G/A | SYNONYMOUS_VARIANT | |
710757 | Benign: not provided | 15,239,479(-) | C/T | SYNONYMOUS_VARIANT | |
710758 | Benign: not provided | 15,244,571(-) | C/T | SYNONYMOUS_VARIANT | |
718290 | Benign: not provided | 15,238,785(-) | C/A | MISSENSE_VARIANT | |
718319 | Benign: not provided | 15,239,151(-) | G/A | SYNONYMOUS_VARIANT |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
dgv3442n100 | CNV | loss | 25217958 |
esv3382180 | CNV | insertion | 20981092 |
esv34154 | CNV | loss | 18971310 |
nsv1078911 | CNV | insertion | 25765185 |
nsv474976 | CNV | novel sequence insertion | 20440878 |
nsv578717 | CNV | loss | 21841781 |
nsv953983 | CNV | deletion | 24416366 |
Disorder | Aliases | PubMed IDs |
---|---|---|
nut midline carcinoma |
|
|
exophthalmic ophthalmoplegia |
|
|
hyperglobulinemic purpura |
|
|
dermatitis, atopic, 7 |
|
|
ureteral obstruction |
|
|